Galectin Therapeutics Inc. · NASDAQ:GALT
Galectin Therapeutics — Investor Presentation (February 2017)
29 slides from Galectin Therapeutics's investor presentation, Feb 2, 2017
Slide 1: Corporate Presentation February 2, 2017
Corporate Presentation February 2, 2017 NASDAQ: GALT www.galectintherapeutics.com © 2017 Galectin Therapeutics Inc. Exhibit 99.1
Slide 2: Forward-Looking Statements
© 2016 Galectin Therapeutics | NASDAQ:GALT This presentation contains, in addition to historical information, forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or future financial performance, and use words
Slide 3: Galectin is a Development Phase Biotech Company with an Experienced Team
Peter G. Traber, M.D. President, CEO, CMO Over 30 years relevant experience Recognized leader in gastroenterology and hepatology University of Pennsylvania Chief of Gastroenterology Chairman of Internal Medicine CEO of Health System, Dean of Medicine Baylor College of Medicine, President and CEO Gla
Slide 4: Developing Treatments for Diseases Where Galectin-3 Is Implicated
Developing Treatments for Diseases Where Galectin-3 Protein Is Implicated In Disease © 2016 Galectin Therapeutics | NASDAQ: GALT Galectin-3 Primary Program NASH Cirrhosis Combination Immunotherapy Psoriasis Atopic Dermatitis
Slide 5: Promising Anti-Galectin Lead Drug
Promising Anti-Galectin Lead Drug © 2016 Galectin Therapeutics | NASDAQ: GALT GR-MD-02 is a complex carbohydrate drug that binds to and disrupts galectin-3 function Existing patent coverage through 2031 with multiple US and international patents issued Broad activity in galectin-dependent animal mod
Slide 6: Overall Strategy: Targeting Galectin-3 Is A Platform Technology
Overall Strategy: Targeting Galectin-3 Is A Platform Technology For Multiple Diseases © 2016 Galectin Therapeutics | NASDAQ: GALT Psoriasis Atopic Dermatitis Proof of clinical efficacy in a human disease Primary Program Fatty Liver Disease NASH Cirrhosis Future Possible Indications Disease Indicatio
Slide 7: Fatty Liver Disease (NASH) is Global Epidemic
Large And Unmet Medical Need 1/4 people in the world are affected by fatty liver disease1 Life-time risk of ~20 million liver-related deaths among fatty liver disease patients currently alive1 Global annual market could be $35-40 Billion by 20252 Recent acquisitions confirm NASH opportunity (Tobira
Slide 8: Clinical Progression Of Fatty Liver Disease
Fatty Liver Cirrhosis (5%) (stage 4 fibrosis) 20+ years Asymptomatic Complications Transplant Death 5-10 years 1-5 years Clinical Progression Of Fatty Liver Disease* © 2016 Galectin Therapeutics | NASDAQ: GALT *Rinella M, Charlton M. The globalization of nonalcoholic fatty liver disease: Prevalence
Slide 9: Targeting The Stage Of Fibrosis That Increases Mortality
Galectin Therapeutics Is Targeting The Stage Of Fibrosis That Increases Mortality © 2016 Galectin Therapeutics NASDAQ:GALT Fibrosis Stage Stage 1 Stage 2 Stage 3 Stage 4 (Cirrhosis) No Increased Mortality Increased Mortality No Symptoms Symptoms/Complications Many companies focused on pre-cirrhotic
Slide 10: Disease Stage in NASH Treatment
Disease Stage in NASH Treatment Fatty liver disease progresses slowly and is asymptomatic until cirrhosis develops Early stages of NASH are difficult to diagnose and one cannot determine which patients will eventually progress to cirrhosis In the early stages of disease, lifestyle changes (weight lo
Slide 11: Significance of Targeting NASH Cirrhosis
Significance of Targeting NASH Cirrhosis Once NASH progresses to cirrhosis, patients are at risk for severe complications, liver failure, and death The only currently available therapy for NASH cirrhosis is liver transplant when clinical progression is severe Once NASH progresses to cirrhosis it is
Slide 12: Galectin-3 Is Critically Important In Development Of Organ Fibrosis
Fundamental Science On Target Is Strong: Galectin-3 Is Critically Important In The Development Of Organ Fibrosis Galectin-3 null mice (no galectin-3) are resistant to fibrosis due to toxin-induced liver toxicity Galectin-3 null mice are also resistant to fibrosis in: Fatty liver disease Kidney fibro
Slide 13: GR-MD-02 Reversed Cirrhosis In Thioacetamide-Treated Rat Model
GR-MD-02 Reversed Cirrhosis In Thioacetamide-Treated Rat Model* Vehicle-Treated GR-MD-02-Treated (Four weekly infusions) Collagen Portal Pressure *Traber PG, Chou H, Zomer E, Hong F, Klyosov A Fiel M-I, Friedman, SL. Therapy of Regression of fibrosis and reversal of cirrhosis in rats by galectin inh
Slide 14: Preclinical Data Shows GR-MD-02 Can Reverse NASH, Fibrosis, And Cirrhosis
Preclinical Data Shows That GR-MD-02 Can Reverse NASH, Fibrosis, And Cirrhosis © 2016 Galectin Therapeutics | NASDAQ: GALT Peer-reviewed publications: 1Traber PG and Zomer E. Therapy of Experimental NASH and Fibrosis with Galectin Inhibitors. PLOS ONE 2013;8:e83481 2Traber PG, Chou H, Zomer E, Hong
Slide 15: Early Clinical Trial Experience Demonstrates GR-MD-02 Is Safe
Fast Track designation from FDA Phase 1 study in normal volunteers was safe and did not cross-react with commonly used drug Phase 1 study in NASH patients with advanced fibrosis showed GR-MD-02 was safe and well tolerated and reached targeted doses Promising Phase 1 data was followed by a short-trea
Slide 16: NASH-CX Phase 2b Clinical Trial
NASH-CX Phase 2b Clinical Trial © 2016 Galectin Therapeutics | NASDAQ:GALT 1 Year of Therapy Indication NASH Cirrhosis Objective Desired Outcome Reduce portal pressure and liver fibrosis Proof-of-concept in NASH cirrhosis Evaluation of registration endpoints NASH-CX Enrollment completed with 162 pat
Slide 17: NASH-CX Phase 2b Clinical Trial: Enrolled Patients and Endpoints
NASH-CX Phase 2b Clinical Trial © 2016 Galectin Therapeutics | NASDAQ:GALT Enrolled Patients NASH cirrhosis with portal hypertension Well compensated disease with no complications of cirrhosis Primary Endpoint Portal pressure (HVPG—hepatic venous pressure gradient) Change in baseline adjusted HVPG f
Slide 18: NASH-CX Phase 2b Clinical Trial: Status as of February 2017
NASH-CX Phase 2b Clinical Trial: Status as of February 2017 © 2016 Galectin Therapeutics | NASDAQ:GALT Completed enrollment with 162 total patients 47 patients have completed all 52 weeks of infusions and 122 patients have completed 26 weeks of infusions 75% of the total number of infusions in the e
Slide 19: Overall Strategy: Platform Technology For Multiple Diseases
Overall Strategy: Targeting Galectin-3 Is A Platform Technology For Multiple Diseases © 2016 Galectin Therapeutics | NASDAQ: GALT Psoriasis Atopic Dermatitis Proof of clinical efficacy in a human disease Primary Program Fatty Liver Disease NASH Cirrhosis Out licensing opportunity
Slide 20: Activity of GR-MD-02 In Moderate-to-Severe Plaque Psoriasis
Activity of GR-MD-02 In Moderate-to-Severe Plaque Psoriasis Psoriasis is immune-mediated chronic skin inflammation associated with NASH. One patient treated with GR-MD-02 in NASH Phase 1 trial had long-term remission of psoriasis All 5 patients treated in Phase 2a open label trial showed improvement
Slide 21: GR-MD-02 Has Efficacy In Moderate-To-Severe Plaque Psoriasis
GR-MD-02 Has Efficacy In Moderate-To-Severe Plaque Psoriasis © 2016 Galectin Therapeutics | NASDAQ: GALT Infusion 4 Infusion 7 Infusion 10 Infusion 13 30 da F/U Moderate-to-severe disease PASI = Psoriasis area & severity score
Slide 22: Investigator-Initiated Study For Severe Atopic Dermatitis
Investigator-Initiated Study For Patients With Severe Atopic Dermatitis (AD) AD is a chronic pruritic (itching), immune-mediated, inflammatory skin disease that for some adult patients can be severe and debilitating Important unmet medical need in adults with severe disease who are not adequately tr
Slide 23: GR-MD-02 Study in Severe Atopic Dermatitis Positive Interim Results
GR-MD-02 Study in Severe Atopic Dermatitis Positive Interim Results © 2016 Galectin Therapeutics | NASDAQ:GALT Patient Baseline EASI SCORAD Week 6 EASI (% Δ) SCORAD (% Δ) Week 12 EASI (% Δ) SCORAD (% Δ) Week 18 EASI (% Δ) SCORAD (% Δ) 1* 39.55 67.6 14 (-65%) 30 (-56%) 15.9 (-60%) 33.1 (-51%) 11.6 (-
Slide 24: Next Steps For Severe Skin Diseases
Next Steps For Severe Skin Diseases Moderate-to-severe plaque psoriasis There are currently multiple effective biological agents on the market All biologics have some degree of serious side effects and are expensive Potential market for GR-MD-02 if focused on a safe and less expensive alternative th
Slide 25: Overall Strategy: Platform Technology For Multiple Diseases
Overall Strategy: Targeting Galectin-3 Is A Platform Technology For Multiple Diseases © 2016 Galectin Therapeutics | NASDAQ: GALT Psoriasis Atopic Dermatitis Proof of clinical efficacy in a human disease Primary Program NASH Cirrhosis Out licensing opportunity Future Possible Indications Disease Ind
Slide 26: Focus on Immunotherapy
© 2016 Galectin Therapeutics | NASDAQ:GALT Focus on Immunotherapy Galectin-3 secreted by cancer cells into the tumor microenvironment reduces the ability of immune system to fight cancer Critical Collaboration Established Providence Cancer Center in Portland, Oregon Performed preclinical studies sho
Slide 27: Combination Cancer Immunotherapy
© 2016 Galectin Therapeutics | NASDAQ:GALT Combination Cancer Immunotherapy Combination P1b trials conducted at Providence Cancer Center Advanced Melanoma: GR-MD-02 In Combination With Yervoy® Advanced Melanoma: GR-MD-02 In Combination With KEYTRUDA® KEYTRUDA trial expanded to include head and neck
Slide 28: Summary of Anti-Galectin Therapy Program With GR-MD-02
Summary of Anti-Galectin Therapy Program With GR-MD-02 Novel antigalectin-3 drug compound that can modulate immune system and may improve multiple diseases Strong patent portfolio and extensive pre-clinical and early clinical data demonstrates strong safety profile and tolerability Lead indication o
Slide 29: Thank you!
Thank you! © 2016 Galectin Therapeutics | NASDAQ: GALT Galectin-3 Primary Program NASH Cirrhosis Combination Immunotherapy Psoriasis Atopic Dermatitis Easily accessible, in depth information on programs: http://perspectives.galectintherapeutics.com/
Galectin Therapeutics — Investor Presentation (February 2017) on 6ix